11月10日 - ** 药物开发商AnaptysBioANAB.O股价下跌14%至34.27美元，创下逾三周以来最差表现
** 该公司称将停止开发治疗溃疡性结肠炎的试验性药物rosnilimab，因为该疗法在一项中期临床试验中未能显示出足够的疗效
** 溃疡性结肠炎是一种慢性肠道疾病，会引起消化道炎症和溃疡
** ANAB称rosnilimab安全且耐受性良好，但12周后未能改善症状
** 停止试验有望节省至少 1000 万美元；公司将专注于类风湿关节炎的药物试验 - ANAB
** 包括本交易日的走势在内，该股今年累计上涨约 154
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.